{
    "info": {
        "nct_id": "NCT03906071",
        "official_title": "A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE",
        "inclusion_criteria": "* Diagnosis of Non-Squamous Non-Small Cell Lung Cancer\n* Receipt of at least one but not more than two prior treatment regimens in the advanced setting\n* Prior treatment with PD-1/PD-L1 checkpoint inhibitor therapy and platinum-based chemotherapy in combination or in sequence (i.e., platinum-based chemotheraphy followed by checkpoint inhibitor therapy)\n* Most recent treatment regimen must have included a checkpoint inhibitor therapy with radiographic disease progression on or after treatment\n* Candidate to receive docetaxel as second or third line therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Uncontrolled brain metastases\n* Tumors that have tested positive for EGFR, ROS1, ALK mutations, or ALK fusions\n* Unacceptable toxicity with prior checkpoint inhibitor therapy\n* Receipt of systemic anti-cancer therapy post checkpoint inhibitor therapy, other than maintenance chemotherapy\n* Impaired heart function",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Receipt of at least one but not more than two prior treatment regimens in the advanced setting",
            "criterions": [
                {
                    "exact_snippets": "Receipt of at least one but not more than two prior treatment regimens in the advanced setting",
                    "criterion": "number of prior treatment regimens in the advanced setting",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "regimens"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "regimens"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with PD-1/PD-L1 checkpoint inhibitor therapy and platinum-based chemotherapy in combination or in sequence (i.e., platinum-based chemotheraphy followed by checkpoint inhibitor therapy)",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with PD-1/PD-L1 checkpoint inhibitor therapy",
                    "criterion": "PD-1/PD-L1 checkpoint inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... platinum-based chemotherapy",
                    "criterion": "platinum-based chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in combination or in sequence (i.e., platinum-based chemotheraphy followed by checkpoint inhibitor therapy)",
                    "criterion": "sequence or combination of therapies",
                    "requirements": [
                        {
                            "requirement_type": "administration pattern",
                            "expected_value": [
                                "combination",
                                "sequence"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of Non-Squamous Non-Small Cell Lung Cancer",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of Non-Squamous Non-Small Cell Lung Cancer",
                    "criterion": "Non-Squamous Non-Small Cell Lung Cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Most recent treatment regimen must have included a checkpoint inhibitor therapy with radiographic disease progression on or after treatment",
            "criterions": [
                {
                    "exact_snippets": "Most recent treatment regimen must have included a checkpoint inhibitor therapy",
                    "criterion": "most recent treatment regimen",
                    "requirements": [
                        {
                            "requirement_type": "inclusion of checkpoint inhibitor therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "radiographic disease progression on or after treatment",
                    "criterion": "radiographic disease progression",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "on or after checkpoint inhibitor therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Candidate to receive docetaxel as second or third line therapy",
            "criterions": [
                {
                    "exact_snippets": "Candidate to receive docetaxel",
                    "criterion": "docetaxel therapy",
                    "requirements": [
                        {
                            "requirement_type": "candidate status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as second or third line therapy",
                    "criterion": "line of therapy",
                    "requirements": [
                        {
                            "requirement_type": "line number",
                            "expected_value": [
                                "second",
                                "third"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Uncontrolled brain metastases",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Impaired heart function",
            "criterions": [
                {
                    "exact_snippets": "Impaired heart function",
                    "criterion": "heart function",
                    "requirements": [
                        {
                            "requirement_type": "impairment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unacceptable toxicity with prior checkpoint inhibitor therapy",
            "criterions": [
                {
                    "exact_snippets": "Unacceptable toxicity with prior checkpoint inhibitor therapy",
                    "criterion": "toxicity with prior checkpoint inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "unacceptable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receipt of systemic anti-cancer therapy post checkpoint inhibitor therapy, other than maintenance chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Receipt of systemic anti-cancer therapy post checkpoint inhibitor therapy",
                    "criterion": "systemic anti-cancer therapy receipt after checkpoint inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other than maintenance chemotherapy",
                    "criterion": "maintenance chemotherapy receipt after checkpoint inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumors that have tested positive for EGFR, ROS1, ALK mutations, or ALK fusions",
            "criterions": [
                {
                    "exact_snippets": "Tumors that have tested positive for EGFR",
                    "criterion": "EGFR mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Tumors that have tested positive for ... ROS1",
                    "criterion": "ROS1 mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Tumors that have tested positive for ... ALK mutations",
                    "criterion": "ALK mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Tumors that have tested positive for ... ALK fusions",
                    "criterion": "ALK fusion status",
                    "requirements": [
                        {
                            "requirement_type": "fusion presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}